Hip osteonecrosis is a pathological condition resulting from cellular impairment from reductions in osteoblast activity and the local mesenchymal stem cell population. Cell-based therapies could correct such deficiencies by providing stem and other progenitor cells potentially to improve the local cellular environment in the affected hip. A rationale for the use of cytotherapy as well as a description of the technique of autologous bone marrow concentrate implantation are provided in the context of treating hip osteonecrosis. Current problems and future challenges with cytotherapy and associated techniques are discussed.
aDepartment of Orthopaedic Surgery, Juntindo University, Tokyo, Japan
bUniversity Paris East (UPEC), Hôpital Henri Mondor, 94010 Creteil, France
cCelling Biosciences, Austin, Texas
Financial Disclosure: The authors report no financial conflicts of interest.
Correspondence to Philippe Hernigou, MD, Department of Orthopaedic Surgery, University Paris East (UPEC), Hôpital Henri Mondor, 94010, Creteil, France Tel: +33149812601; fax: +33149812608; e-mail: email@example.com